MedPath

Treatment Of Bronchiolitis With Heated Humidified High Flow Nasal Cannula - Prospective And Retrospective Research

Phase 3
Conditions
Bronchiolitis
Interventions
Device: HeatedHumidifiedHighFlowNasalCannula
Registration Number
NCT02366715
Lead Sponsor
Rabin Medical Center
Brief Summary

Bronchiolitis is an acute lower airway infection caused by a viral infection. It is a major cause of winter admissions to pediatric wards. Accepted therapies include oxygen support and IV fluids, whereas other supportive therapies such as inhalations are of questionable benefit. Moderate to severe cases are a source of distress to patient, parents and medical staff often necessitating Pediatric Intensive Care Unit admission. Heated Humidified High Flow Nasal Cannula (HHHFNC) therapy has been shown lately to improve the work of breathing, oxygen saturation, and CO2 pressure (PCO2) values as well as decrease PICU admissions and intubation rates. We planned a prospective and retrospective study in order to check the feasibility of using HHHFNC in a primary pediatric ward and its effect on clinical well being, respiratory status and PICU admission.

Detailed Description

Supportive Care, Single Group Assignment, Open Label, Non-Randomized, Efficacy Study

The research is devised as follows:

Prospective section: We will enroll children 0-2 years old, diagnosed with Bronchiolitis in our ward (Pediatrics C) during the months of November-March 2014-2016. Children will be evaluated according to a Bronchiolitis Severity Score devised by Wang and Co which was successfully used in previous research. Children answering criteria for moderate or severe Bronchiolitis according to Wang and Co. will be enrolled pending written consent by both parents.

Our prediction is to enroll a total of 200 children during the 2 winter seasons during 2014-2016.

Retrospective section: We will examine up to 200 cases of children aged 0-2 years hospitalized due to Bronchiolitis in Pediatrics C during 2014-2016 which were not enrolled in our research (due to lack of consent/unavailable HHHFNC etc.). We will compare clinical data and vital parameters between the groups treated with HHHFNC and those who were not.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
200
Inclusion Criteria

in age interval, diagnosed with Bronchiolitis

Exclusion Criteria

Chronic heart/lung disease, immunocompromised state

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
HeatedHumidifiedHighFlowNasalCannulaHeatedHumidifiedHighFlowNasalCannulaTreatment for moderate-severe cases of Bronchiolitis while monitoring medical parameters
Primary Outcome Measures
NameTimeMethod
Changes in Bronchiolitis Severity Score gradeduring the 20-40 hours of the protocol

The grade in the Bronchiolitis Severity Score (0-12) reflects a general improvement or deterioration in any of these 5 parameters - oxygen saturation, breath rate, general appearance, degree of dyspnea and lung auscultation result.

Secondary Outcome Measures
NameTimeMethod
Ability to take in food orallyduring the 20-40 hours of the protocol

Whether the child has been able to feed - yes or no.

Medical interventionsduring the 20-40 hours of the protocol

Any medication given to the child during the time of the protocol including IV fluids, inhalations, diuretics.

Number of Pediatric Intensive Care Unit (PICU) admissionsThe whole hospitalization period of the child

Whether the child needed admission to PICU

CO2 pressureduring the 20-40 hours of the protocol

(in mmHg) measured by a transcutaneous sensor.

Trial Locations

Locations (1)

Schneider Medical Center of Israel

🇮🇱

Petah Tikva, Israel

© Copyright 2025. All Rights Reserved by MedPath